Evidence map›Paper›PMID 42721494›Full record

ArticleVirus research2026

Calu-3 cells as novel efficient cell culture system for Borna disease virus 1 (BoDV-1).

Lisa Arnold, Vanessa Schwarz, Gertrud Knoll, André Gessner, Barbara Schmidt, Markus Bauswein

Abstract read
In one paragraph

Article in Virus research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lisa ArnoldInstitute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany.
Vanessa SchwarzInstitute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany.
Gertrud KnollInstitute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany.
André GessnerInstitute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.
Barbara SchmidtInstitute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.
Markus BausweinInstitute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany. Electronic address: markus.bauswein@ukr.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Borna disease virus 1 (BoDV-1) is the causative agent of zoonotic infections resulting in severe encephalitis with a high case-fatality rate in humans. To search for an efficient in-vitro cell culture system for the generation of BoDV-1 virus stocks, we compared different human cell lines (A549, Caco-2, Calu-3, oligodendroglioma cells, SK-N-AS) and Vero cells with respect to BoDV-1 infection kinetics. While all cell lines included in the study supported the release of BoDV-1 RNA and its intracellular accumulation at the end of the experiment, viral RNA was detected in the supernatant of Calu-3 cells as early as six days post infection. In addition, two weeks post infection RNA loads remained highest in the supernatant of this cell line, which also yielded highest BoDV-1 RNA copies per cell. Using the ratio of BoDV-1 RNA in the supernatant and the cell pellet as a surrogate marker, Calu-3 cells released BoDV-1 RNA most efficiently. Notably, favipiravir (T-705), a drug with a described cell-type dependent inhibitory activity against BoDV-1 in vitro, which has been used as an off-label therapy in some cases of human BoDV-1 infection, did not reduce BoDV-1 RNA shedding into the supernatant of permanently infected Calu-3 cells and had only a limited effect in a de-novo infection model. In conclusion, our results underline the broad viral tropism of BoDV-1 in vitro and first describe a high release efficiency for BoDV-1 RNA in Calu-3 cells.

Indexed as

Borna disease virus 1 (BoDV-1)Calu-3Cell cultureFavipiravir (T-705)ReplicationVeroVirus stock

Identifiers

PMID42721494
PMCPMC13584004

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.